Prognostic tumor sequencing panels frequently identify germ line variants associated with hereditary hematopoietic malignancies-Reference-Cited by-同舟云学术

Prognostic tumor sequencing panels frequently identify germ line variants associated with hereditary hematopoietic malignancies

Published:2018-01-22 Issue:2 Volume:2 Page:146-150
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Drazer Michael W.¹²^ORCID,Kadri Sabah³,Sukhanova Madina¹,Patil Sushant A.³,West Allison H.¹,Feurstein Simone¹,Calderon Dalein A.¹,Jones Matthew F.¹,Weipert Caroline M.¹,Daugherty Christopher K.¹,Ceballos-López Adrián A.⁴,Raca Gordana¹,Lingen Mark W.³,Li Zejuan²,Segal Jeremy P.³,Churpek Jane E.¹,Godley Lucy A.¹²

Affiliation:

1. Section of Hematology/Oncology, Department of Medicine, The University of Chicago Comprehensive Cancer Center,

2. Department of Human Genetics, and

3. Department of Pathology, The University of Chicago, Chicago, IL; and

4. Section of Hematology, Department of Internal Medicine, Clinica de Mérida, Mérida, Mexico

Abstract

Key Points NGS-based prognostic panels may identify individuals at risk for HHMs despite not being designed for this purpose. Variant allele frequency >0.4 and gene of interest may be predictive of germ line origin.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/2/2/146/879848/advances013037.pdf

Reference16 articles.

1. How I diagnose and manage individuals at risk for inherited myeloid malignancies;University of Chicago Hematopoietic Malignancies Cancer Risk Team;Blood,2016

2. Identifying familial myelodysplastic/acute leukemia predisposition syndromes through hematopoietic stem cell transplantation donors with thrombocytopenia;Churpek;Blood,2012

3. Identifying inherited and acquired genetic factors involved in poor stem cell mobilization and donor-derived malignancy;Rojek;Biol Blood Marrow Transplant,2016

4. Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting;He;Blood,2016

5. Clinical validation of a next-generation sequencing genomic oncology panel via cross-platform benchmarking against established Amplicon sequencing assays;Kadri;J Mol Diagn,2017

Cited by 86 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The impact of next-generation sequencing for diagnosis and disease understanding of myeloid malignancies;Expert Review of Molecular Diagnostics;2024-07-02

2. Childhood myelodysplastic syndromes: Is cytoreductive therapy useful before allogeneic hematopoietic stem cell transplantation?;HemaSphere;2024-07

3. Germline assessment for alloHSCT candidates over 50 years: A ‘Fast‐Track’ screening in myeloid neoplasms;British Journal of Haematology;2024-04-19

4. Genomic testing for germline predisposition to hematologic malignancies;Blood Research;2024-03-08

5. Risk of cancer in relatives of patients with myelodysplastic neoplasia and acute leukemias;Cancer Epidemiology;2024-02